Lancet Diabetes & Endocrinology

Papers
(The H4-Index of Lancet Diabetes & Endocrinology is 69. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-10-01 to 2025-10-01.)
ArticleCitations
What's preventing us from curbing the obesity crisis?1076
Mark Atkinson: bringing two worlds together757
Direct-to-consumer services: improving access to care for people with diabetes and obesity647
Long-term trial outcomes of Roux-en-Y gastric bypass and one anastomosis gastric bypass: tipping the scale628
World Health Assembly ratifies first global diabetes targets485
South Africa to produce insulin for Africa in 2024464
Metastases to the thyroid gland: how does this affect cytohistological diagnoses?461
Correction to Lancet Diabetes Endocrinol 2022; 10: 489–98458
Better testing and labelling of drugs for people with obesity453
Artificial intelligence and diabetes: time for action and caution414
Type 1 diabetes screening: need for ethical, equity, and health systems perspective404
Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial392
Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials354
Effect of sodium–glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, p294
A framework for improving diabetes care in humanitarian emergencies237
Implications of technology guidelines for low-income and middle-income countries231
Outcomes in children of women with type 2 diabetes exposed to metformin versus placebo during pregnancy (MiTy Kids): a 24-month follow-up of the MiTy randomised controlled trial224
Reassessing driving safety in diabetes202
Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years in the US Diabetes Prevention Program randomised clinical trial194
Estimating direct tissue effects versus weight loss effects of incretin-based drugs for obesity on various chronic conditions186
Anand Hardikar: a scientific nomad searching for the truth172
Correction to Lancet Diabetes Endocrinol 2022; published online Sept 29. https://doi.org/10.1016/S2213-8587(22)00252-2165
Association of glycaemic index and glycaemic load with type 2 diabetes, cardiovascular disease, cancer, and all-cause mortality163
Obesity in people living with type 1 diabetes161
International Federation for the Surgery of Obesity statement on metabolic bariatric surgery after pharmacotherapy-induced weight loss in clinical obesity155
Multiple endocrine neoplasia type 1 (MEN1): recommendations and guidelines for best practice149
Jennifer Manne-Goehler: at the crossroads of pandemics148
The uncomfortable truth about kidney disease in type 1 diabetes147
Association of glycaemic index and glycaemic load with type 2 diabetes in the PURE study146
Levothyroxine treatment in euthyroid women positive for thyroid peroxidase antibodies and recurrent pregnancy loss141
Retraction and republication—Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses135
What does renal failure teach us about our National Health System?130
Correction to Lancet Diabetes Endocrinol 2025; published online April 7. https://doi.org/10.1016/S2213-8587(25)00087-7128
Explaining the high rate of progression from prediabetes to type 2 diabetes in China128
The role of nurses in diabetes care: challenges and opportunities126
Putting wellbeing at the core of diabetes care126
The changing character of diabetes complications126
A roadmap for integrating mental health and diabetes services119
Sodium–glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials118
Lebanon: insulin out of reach after subsidies lifted116
Glucose-lowering drugs with cardiovascular benefits as modifiers of critical elements of the human life history112
Behind the scenes: epigenetic mechanisms rule the roost in pubertal timing106
The Human Insulin Thermal Solution project—a private sector initiative to address the thermostability of insulin105
Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial – Authors' reply104
Glycaemic index as part of the diabetes prevention strategy100
Healthy weight for the next generation's health in China97
Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis96
Rising diabetes diagnosis in long COVID94
The promise and hope of GLP-1 receptor agonists91
Challenging diabetes stigma starts and ends with all of us91
Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study88
The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 202086
Childhood obesity: a growing pandemic86
Homing in on the causes of male infertility82
Is it time to re-assess the development of thyroid function reference ranges?81
Women in diabetes research: stepping towards equity81
Correction to Lancet Diabetes Endocrinol 2022; 10: 407–1780
Blood pressure control according to type 2 diabetes status80
Correction to Lancet Diabetes Endocrinol 2023; 11: 402–1376
Balancing hormonal shifts: exploring the impact of ageing and dietary restriction74
Diabetes: knowing your risk matters73
Correction to Lancet Diabetes Endocrinol 2022; 10: 481–8372
Bothersome vasomotor symptoms: a potential early clinical marker of perimenopause?71
Understanding the mechanism of prediabetes remission in young people70
CONCEPTT to care: the science of implementation in diabetes care70
Rare variants in the MECP2 gene in girls with central precocious puberty: a translational cohort study70
Aberrant hormone receptors regulate a wide spectrum of endocrine tumors69
Improving HbA1c levels with advanced hybrid closed-loop therapy69
A novel diagnostic score for diagnosing arginine vasopressin deficiency (central diabetes insipidus) or primary polydipsia with basal laboratory and clinical parameters: results from two international69
Gender equality: timely and timeless69
0.14252114295959